The regulation of the cell cycle is a fundamental process ensuring the accurate replication and division of cells. Central to this regulation are the Cdc25 phosphatases, which activate ...
The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...
A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer treatment without chemotherapy.
Researchers discovered an antioxidant, glutathione, that cancer cells appear to be "addicted to" as fuel, opening new ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
The ability of mutations to cause cancer depends on how fast they force cells to divide, Sinai Health researchers have found. The study, led by Dr. Rod Bremner, a Senior Investigator at the ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
A fasting-derived ketone metabolite reshapes CAR T cell metabolism and gene activity, boosting immune cell expansion, energy ...
In 2016, Colinda Scheele, a cancer biologist at Catholic University Leuven, was studying how chemotherapy affects breast cancer cells in mice. However, she observed an inconsistency: Some cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results